Losartan Lowers CV Complications of Hypertension

NEW YORK (MedscapeWire) Mar 26 — A head-to-head trial reported in the March 23 issue of The Lancet shows that losartan is better than atenolol at reducing cardiovascular disease and stroke, with similar degrees of blood pressure lowering and fewer adverse effects.
"Blood-pressure reduction achieved with beta-blockers and diuretics is thebest recorded intervention to date for the prevention of cardiovascularmorbidity and death in patients with hypertension," write Björn Dahlöf from Östra University Hospital, Sweden, and colleagues from the Losartan Intervention for Endpoint reduction inHypertension study (LIFE). "Left ventricular hypertrophy (LVH) is a strongindependent indicator of risk of cardiovascular illness and death."

In this randomized, multicenter trial based in Europe and the UnitedStates, 9193 hypertensive patients with LVH, aged 55-80 years, receivedeither losartan-based or atenolol-based antihypertensive treatment for atleast 4 years and until 1040 patients had a primary cardiovascular eventdefined as death, myocardial infarction, or stroke.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים